Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases.

@article{Bi2008PreclinicalFA,
  title={Preclinical factors affecting the pharmacokinetic behaviour of tanshinone IIA, an investigational new drug isolated from Salvia miltiorrhiza for the treatment of ischaemic heart diseases.},
  author={H-C Bi and Zhong Zuo and Xianzhi Chen and C Xu and Y-Y Wen and H Sun and L-Z Zhao and Yu Pan and Yanli Deng and P-Q Liu and L-Q Gu and Zhi-yong Huang and S Zhou and Min Huang},
  journal={Xenobiotica; the fate of foreign compounds in biological systems},
  year={2008},
  volume={38 2},
  pages={185-222}
}
Tanshinone IIA (TSIIA) is a major active triterpenoid isolated from Salvia miltiorrhiza. The purposes of this study were to investigate various preclinical factors that determined the pharmacokinetics of TSIIA. After oral dosing at 6.7, 20, and 60 mg kg(-1), TSIIA was detected mainly as glucuronidated conjugate (TSIIAG) with only small amounts of the unchanged in the plasma. TSIIA was predominantly excreted into the bile and faeces as TSIIAG, and urine to a minor extent. The C(max) and AUC(0… CONTINUE READING
16 Citations
0 References
Similar Papers

Citations

Publications citing this paper.
Showing 1-10 of 16 extracted citations

Similar Papers

Loading similar papers…